The Incidence of Hereditary Breast and Ovarian Cancer Higher in India Compared to Western Countries

/ -- Strand Life Sciences Organizes a Symposium in Noida to Talk About Their Experience of Screening More Than Thousand Patients of Breast and Ovarian Cancer
A symposium was organized at Hotel Park Ascent in Noida by Strand Life Sciences to bring together domain experts from gynaecology and IVF to discuss this trend of higher incidence of breast and ovarian cancer and associated screening for early diagnosis. Dr. Ramesh Hariharan, CEO of Strand Life Sciences, was present at this occasion and shared Strand's capabilities as a diagnostic lab to screen such cancers. With the acquisition of Quest Diagnostics' India business, Strand is now better placed to cater to the North Indian market as well. He added, "We bring cutting-edge diagnostics to India with world class quality at affordable prices. This will help us all in our fight against cancer."

Dr. Pooja Agrawal, from Strand Life Sciences, shared that the incidence of hereditary breast and ovarian cancer is much higher in India as compared to western countries and cited data from an original research paper from Strand along with cancer cases where Strand could help patients. Dr. Agrawal said, "It is not only important but also critical that early screening of cancer, which is cost-effective and comprehensive, should be adopted by the healthcare industry in India to reduce the high mortality rate in patients."
About Strand Life Sciences